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Abstract: The blood-brain barrier (BBB) has a significant
contribution to the protection of the central nervous sys-
tem (CNS). However, it also limits the brain drug delivery
and thereby complicates the treatment of CNS diseases.
The development of safe methods for an effective delivery
of medications and nanocarriers to the brain can be a
revolutionary step in the overcoming this limitation. Here,
we report the unique properties of the lymphatic system to
deliver tracers and liposomes to the brainmeninges, brain
tissues, and glioma in rats. Using a quantum-dot-based
1267 nm laser (for photosensitizer-free generation of
singlet oxygen), we clearly demonstrate photostimulation
of lymphatic delivery of liposomes to glioma as well
as lymphatic clearance of liposomes from the brain.
These pilot findings open promising perspectives for
photomodulation of lymphatic delivery of drugs and
nanocarriers to the brain pathology bypassing the BBB.
The lymphatic “smart” delivery of liposomes with
antitumor drugs in the new brain tumor branches might
be a breakthrough strategy for the therapy of gliomas.
Keywords: glioma; liposomes; lymphatic backroad to the
brain; photostimulation; rats.
1 Introduction
The blood-brain barrier (BBB) is a major obstacle for
effective delivery of therapeutic compounds to the brain,
imposing size and biochemical restriction on the passage
of molecules [1]. Gliomas are the most common tumor of
the central nervous system (CNS). However, the presence of
the BBB blocks an effective delivery of anticancer drugs
into brain tumors and leads to treatment failure. Indeed,
malignant gliomas (MG) are highly invasive and use the
perivascular space (PVS) for invasion and co-opt existing
vessels as a satellite tumor form [2]. In the early stages,
glioma develops through normal brain vessels with the
intact BBB that limits a pharmacological treatment of the
newly formed tumor. A cure for MG will only be possible if
the invasive brain tumor branches will be adequately
treated [3, 4]. Therefore, there is a growing need to develop
safe methods bypassing the BBB and blood-tumor barriers
for effective therapy of MG.
The lymphatic system of the brain and the meninges
can be a good candidate for brain drug delivery. The clas-
sical characteristic of the CNS is a lack of lymphatic vessels
(LVs). However, it has become more and more evident that
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the CNS is not a passive “immune-privileged” organ, but it
is rather a compartment demonstrating highly immune
responses [5–7]. Recent studies have identified entry and
exit points for immune cells, cytokines, and brain-derived
antigens or waste molecules through distinct anatomical
routes in the meninges [6–8]. The meningeal “door” might
allow for the BBB bypass, providing an interface for pe-
ripheral immune system interactionwith theCNS, and could
play an important role in drug delivery to the MG.
In our previous work, we reported photostimulation
(PS) of themeningeal lymphatic vessels (MLVs) [5–11] using
a quantum-dot 1267 nm laser, which can directly generate
singlet oxygen (1O2) from the triplet oxygen state without
photosensitizers [12, 13]. We uncovered that PS stimulates
the clearance ofmacromolecules from the brain viaMLVs as
well as PS causes an increase in the permeability of the
lymphatic endothelium to macrophages [9, 10]. In our pilot
experiments on rats, we demonstrated laser-suppression of
glioma growth that was associated with the activation of
the lymphatic drainage system, stimulation of apoptosis,
decrease of autophagy, and proliferation of glioma cells [11].
These findings open new strategies for therapy of brain
diseases, including glioma by modulation of the lymphatic
functions via PS.
Liposomes, as nanoscale drug carriers, are a prom-
ising drug delivery system [14–21] that can encapsulate
both hydrophilic and hydrophobic drugs. Hydrophilic
drugs are encapsulated in an aqueous core, and lipophilic
drugs are encapsulated in a hydrophobic region of the
lipid bilayer. The lipid bilayer of liposomes is composed
on the basis of phospholipids and is very similar to cell
membranes. In addition, liposomes offer numerous
advantages, including targeting capability, long-term
efficacy, improved drug stability, lowered drug toxicity,
and increased circulation time [15, 18]. Liposomes are also
capable of achieving targeting by modifying proteins,
antibodies, aptamers, or polypeptides [14]. These prop-
erties of liposomes have attracted interest in their devel-
opment as promising transporters to deliver antitumoral
drugs to the CNS and thus, to improve brain drug targeting
and therapeutic efficiency [14, 16, 17].
Among different types of liposomes, those incorpo-
rated with gangliosides are of greatest interest for brain
drug delivery [17, 19]. Gangliosides consist of a hydrophilic
sialic acid terminal sugar and a hydrophobic ceramide
moiety, theywidely exist in neural tissue of vertebrates and
have been reported to modulate ion transport, neuronal
differentiation, G protein-coupled receptors, immune sys-
tem reactivity, and neuroprotective signaling [20, 21]. More
importantly, liposomes consisted of one of a ganglioside
monosialotetrahexosylganglioside (GM1) can overcome the
BBB and treat neurological disease [17, 19]. Recently we
demonstrated photodynamic opening of the BBB for the
intravenously injected GM1-liposomes [22].
In this work, we aim to study a lymphatic delivery of
GM1-liposomes to the brain and fluorescent glioma in rats,
bypassing the BBB. We also sought to examine the mod-
ulation of lymphatic transport of liposomes by PS to and
from the rat brain.
2 Results
2.1 Lymphatic backroad to the brain and the
meninges
The deep cervical lymph nodes (dcLNs) play a crucial role
in the crosstalk between the brain and the peripheral
lymphatic system [6, 23–27]. It is assumed that the cervical
lymph nodes can be an anatomical platform for brain drug
delivery [7, 27]. Here, we test this hypothesis and study a
lymphatic delivery of liposomes and Evans Blue dye to the
brain meninges and tissues after its injection into dcLN.
To determine the effective time for lymphatic delivery
of tracer to the meninges, we analyzed the presence of
Evans Blue in the meninges 1, 2, and 3 h after dye injec-
tion. Figure 1 a-c demonstrate confocal images of the
meninges labeled with the lymphatic marker, such as
Lyve-1, and the time-dependent distribution of Evans Blue
in the lymphatic network. Quantitative analysis revealed
a gradual increase in time of the Evans Blue fluorescent
signal in the meninges. The fluorescence of Evans Blue in
the meninges reached a maximum of 3 h after the dye
injection in dcLN. Indeed, the intensity of the fluorescent
signal from Evans Blue in the meninges was 3.90-fold
higher (p < 0.001) versus 1 h after the dye injection and
1.59-fold higher (p < 0.001) versus 2 h after the clearance of
Evans Blue from the brain (Figure 1f). These findings
allowed us to conclude that 3 h after injection of tracer is
enough for its lymphatic delivery to the meninges.
Therefore, this time was used in our further experiments.
A number of studies showed a retrograde flow in the
PVS in the brain that is also typical for the peripheral
lymphatic system [28–30]. To answer the question, how
tracers are delivered to the brain from dcLN, we monitored
in vivo the presence of Evans Blue in the meninges using
ligation of the cervical LVs in upper and lower dcLN
(Figure 1g). Our finding showed the appearance of dye in
the meninges (3 h after its injection into the dcLN) in the
case of ligation of the cervical LVs lower but not upper
dcLN suggesting a retrograde lymphatic flow of Evans blue
from dcLN to the brain.
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Figure 1: The lymphatic backroad to the brain: a–c – Representative images of the distribution of Evans Blue in the meninges labeled with
Lyve-1 in rats 1 h (a), 2 h (b), and 3 h (c) after the dye injection in dcLN; d – Representative images of the presence of Evans Blue along the
meningeal blood vessels labeled with marker of pericytes (neuron-glial antigen 2 – NG2) 3 h after its injection in dcLN; e – Representative
images of the presence of liposomes along the meningeal blood vessels labeling with NG2 3 h after its injection in dcLN; f – Quantitative
analysis of the signal intensity from Evans Blue in the meninges 1, 2, and 3 h after the dye injection in dcLN, ***p < 0.001 between groups
at t = 1, 2, and 3 h after the dye injection, n = 7 in each time point; g – Schematic illustration of the cervical LVs for the study of lymphatic
pathways of dye delivery from dcLN; h – Real-time confocal imaging of the retrograde lymphatic pathway of Evans Blue delivery to the
meninges 3 h after dye injection in dcLN and ligation of the cervical LVs below dcLN.
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Next, we analyzed a lymphatic delivery of liposomes to
the meninges 3 h after its injection into the dcLN. Figure 1e
illustrates the perivascular route of lymphatic delivery of
liposomes to the meninges. This is like the results we
observed using Evans Blue (Figure 1d). These data suggest
that both tracers (liposomes and Evans Blue) were deliv-
ered to the meninges via MLVs, which are localized along
themeningeal veins [6, 24]. To confirm this fact, we studied
the lymphatic delivery of liposomes to the meninges using
the lymphatic (lymphatic vessel endothelial hyaluronan
receptor 1, Lyve-1) and the blood vessel (neuron-glial
antigen 2, NG2) markers. Figure 2 clearly demonstrates the
presence of liposomes in MLVs but not in the meningeal
blood vessels, suggesting a lymphatic pathway of their
traveling from dcLN to the meninges.
Previous work has demonstrated that LVs are present
directly in the human brain debating that the cerebral LVs
can deliver metabolites andmolecules from the PVS to the
brain tissue [31]. Although LVs have not been found in the
rodent brain yet, it is reasonable to expect delivery of
liposomes from the PVS directly to the rat brain. To test
this hypothesis, we examined brain slices labeledwith the
astrocytic (glial fibrillary acidic protein, GFAP) and the
blood vessels endothelium (NG2) markers obtained from
rats with the injection of liposomes into the dcLNs (3 h
after injection). Figure 2 demonstrates the distribution of
Figure 2: The lymphatic delivery of liposomes to the brain: a – Representative images of the brain tissues labeled with GFAP (astrocytic
marker) and NG2 (a marker for the pericytes in the blood vessel): b–d – Representative images of the three regions of interest demonstrating
the distribution of liposomes in the brain parenchyma.
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liposomes in the PVS and between the astrocyte endfeet,
i.e. in the brain parenchyma.
Thus, these findings evidently demonstrate that dcLNs
are an anatomical platform for communication between
the brain and the peripheral lymphatic system. The Evans
Blue and liposomes can be delivered from the dcLN to the
brain meninges and parenchyma via the lymphatic
backroad.
2.2 Photomodulation of lymphatic delivery
of liposomes to glioma
In this step, we anticipated answering two questions
(i) whether liposomes deliver to glioma via the lymphatic
pathway and (ii) how does PS modulate this process?
The liposomes were injected into the dcLN of rats with
fluorescent glioma and allowed to circulate in the
lymphatic system for 3 h in both animal groups treated and
untreated by PS (Figure 3d). Additionally, Evans Blue dye
was injected into the tail vein to study the BBBpermeability
in these groups. Figure 3a and b illustrate the confocal
imaging of fluorescent glioma with the spreading of
liposomes in tumor tissues and the leakage of Evans Blue,
suggesting the BBB disruption.
Our findings uncovered that the distribution of lipo-
somes among glioma cells was higher in the PS treated
group versus the untreated animals. Indeed, Figure 3c
shows that the intensity of the fluorescent signal from
liposomes in the brain was 1.5-fold higher (0.53 ± 0.02 a.u.
vs. 0.35 ± 0.05 a.u., p < 0.001, n = 7) in the group PS-treated
versus the untreated animals.
Figure 3: The photostimulation (PS) of lymphatic delivery of liposomes to glioma: a and b– Representative images of liposomes and the Evans
Blue fluorescence in the glioma tissues in the untreated group (a) and the group treated by PS (b); с – Quantification of the intensity of
the fluorescent signal from liposomes in the brain of treated and untreated rats by PS, ***p < 0.001 between groups, n = 7 in each group;
d – Schematic illustration of the experimental design.
O. Semyachkina-Glushkovskaya et al.: Photomodulation of lymphatic delivery of liposomes 5
Figure 4: The photostimulation of lymphatic clearance of liposomes from the brain: a and b – Real-time confocal images and kinetics of the
fluorescent signal intensity (1–4) from liposomes in the cervical LVs after their injection into the cisterna magna in the PS-treated (a) and the
untreated (b) groups. Blue rectangles denote regions of interest (ROIs) used to measure the averaged intensity of fluorescence (1–4); an
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The permeability of the BBB to Evans Blue was
analyzed using the spectrofluorometric assay. The results
revealed that the leakage of Evans Blue was much
lesser in the PS-treated versus the untreated groups
(3.73 ± 0.82 μg/g tissue vs. 7.81 ± 1.20 μg/g tissue,
p < 0.001, n = 7 in each group). Nevertheless, both groups
demonstrated the BBB permeability to Evans Blue
(3.73 ± 0.82 μg/g tissue vs. 0.11 ± 0.09 μg/g tissue, p < 0.001
for the PS-treated group and 7.81 ± 1.20 µg/tissue vs.
0.11 ± 0.09 μg/g tissue, p < 0.001 for the untreated group,
p < 0.001, n = 7 in each groups). Thus, the treated by PS
group demonstrated the more preserved BBB versus the
untreated group. This observation can be explained by the
fact that PS might in parallel stimulate lymphatic clearing
of the molecules from the brain [32]. To confirm this fact, in
the final steps we studied whether PS affects the lymphatic
clearance of liposomes from the brain.
2.3 PS-mediated lymphatic clearance of
liposomes from the brain
In this step, liposomes were injected into the cisterna magna
with further real-time confocal monitoring of their clearance
fromthe subarachnoid spacevia the separated cervical LVs in
the PS-treated and untreated rats (Figure 4g). Our results
showed that liposomes green fluorescence was detected
within the cervical LVs immediately after their intra-cisterna
administration and then the intensity of the fluorescence
gradually decreased with respect to the intensity of Evans
Blue fluorescence. However, when the 1267 nm laser was
turned on, an increase of fluorescence from liposomes was
observed. Figure 4C shows an arbitrary ratio of boron-
dipyrromethene (BODIPY) fluorescence against Evans Blue
fluorescence starting from the moment when the laser was
turnedon (Figures 1, 2, and4) and for the same timeperiod for
the untreated group (Figures 3 and 4) for which the laser was
not applied. Blue rectangles denote regions of interest (ROIs)
chosen to measure the averaged fluorescence intensity.
The data obtained in vivo experiments were confirmed
in ex vivo confocal imaging of dcLN obtained from the same
rats, in which the cervical LV were monitored in real-time.
Figure 4c, d, and h clearly demonstrate the significant
spreading of liposomes in LVs of dcLN that was 3.6-fold
higher in the PS-treated group versus the untreated group
(0.55 ± 0.02 vs. 0.15 ± 0.03, p < 0.001, n = 7). The PS effects
were accompanied by dilation of LVs labeled with Live1/
Prox1. Indeed, the average diameter of LVs was 2.7-fold
bigger in rats after PS than in untreated animals (52.3 ± 2.3
vs. 31.0 ± 1.3 µm, p < 0.001, n = 7).
Thus, these results demonstrate that PS activates the
clearance of liposomes from the subarachnoid space of
the brain via lymphatic pathways.
3 Discussion
To address the overcoming difficulties of effective delivery
ofmedications and nanocarriers to the brain, we tested our
hypothesis that the lymphatic system of the brain and the
meninges can be a good candidate for brain drug delivery
with a focus on glioma. Furthermore, we studied PS effects
on the lymphatic transport of molecules as a promising
tool for the modulation of lymphatic drug delivery to the
brain. Our results clearly demonstrate that dcLNs are an
anatomical structure for a unique communication between
the brain and the peripheral lymphatic network. Indeed,
injection of liposomes and tested tracers in dcLN was
accompanied by their delivery to the meninges, brain pa-
renchyma, and glioma. Our findings are consistent with
other experimental evidence suggesting that dcLNs are a
unique passage, which connects the brain fluid system
and the peripheral lymphatics [6, 9, 10, 23–26]. So, dcLNs
play a crucial role in the crosstalk between the brain and
the peripheral immune system [6, 23, 24]. The injection
of blood in the different brain regions causes a humoral
immune response in mice generated mainly by dcLNs
[25]. Similarly, the injection of serum albumin in the
subarachnoid space induces an antibody production by
cervical lymph nodes in cats [25, 26]. Serum antibody is
reduced after the obligation of the cervical LNs [26]. The
dcLNs play an important role in the exchanges of immune
cells between the microenvironment of brain tumors and
the peripheral immune system [33].
We revealed that molecules (Evans Blue and lipo-
somes) traveled from dcLN to the brain meninges and
arbitrary ratio of BODIPY fluorescence versus fluorescence of Evans Blue since themoment the laser was turned on (1, 2) and for the same time
period for the untreated group (3, 4) for which the laser was not applied. Representative of n = 7 rats of each group. c and d – Representative
images of thepresence of liposomes in dcLNs obtained from the PS-treated (c) and the untreated (d) groups;e and f–Representative imagesof
LVs in dcLNs obtained from the PS-treated (e) and the untreated (f ) groups. Representative of n= 7 rats of each group; h–Quantification of the
intensity of the fluorescent signal from liposomes in dcLNs in the PS-treated and the untreated groups, ***p < 0.001 between groups, n = 7 in
each group; i–Diameter of the cervical LVs in dcLNs in the PS-treated and untreated groups; ***p < 0.001 between groups, n= 7 in each group;
g – Schematic illustration of experimental design.
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parenchyma via the lymphatic backroad. The retrograde
movement of tracers into the brain parenchyma was also
discussed in other works as physiological properties of the
lymphatic/glymphatic mechanisms of exchanges of mol-
ecules between the PVS and the brain parenchyma
[28–30]. Zhao et al. [22] argued that the injection of fluo-
rescent nanoparticles subcutaneously close to the dcLNs is
accompanied by nanoparticles brain delivery through
MLVs. It has shown that the injection of choroid plexus
cells into the ST36 acupuncture point (Stomach 36 or
Zusanli) close to the popliteal LVs causes a neuro-
protective effect in mice with Parkinson’s disease due to
the delivery of injected cells to the brain [34].
In our research, we demonstrate that PS enhances
the lymphatic transport of liposomes to glioma and
the clearance of these nanocarriers from the subarachnoid
space. The infra-red light of 800–1100 nm is widely used
for the PS therapy of various brain diseases [35]. However,
the infra-red PS has a significant drawback in its limited
penetration into the brain due to the high scattering and
heating effect [36]. The light wavelength of 1300 nm has
less scattering and can penetrate deeper into the brain [37].
In our recent work, we revealed that the glioblastoma
growth can be suppressed by a photosensitizer-free laser
treatment using a quantum-dot-based 1267 nm laser diode
[11]. This wavelength, highly absorbed by oxygen, is
capable of turning triplet oxygen into reactive singlet form.
Applying a 372 J/cm2 dose of 1267 nm suppressed glio-
blastoma growth and increased the survival rate from34 up
to 64% presumably via the PS-activated apoptosis, inhi-
bition of the autophagy, proliferation of the tumor cells,
PS of the lymphatic drainage, and clearing functions.
Using the samePS dose anddesign of experiments, herewe
clearly show that PS increases the lymphatic transport of
liposomes to glioma. We assume that the PS effects on the
tone of LVs facilitate lymphatic transport of liposomes to
glioma. Indeed, these effectswere accompanied bydilation
of the cervical LVs. In our recent work, we uncover that PS
dilates MLVs that are associated with PS-mediated stimu-
lation of lymphatic transport of red blood cells from the
brain [38]. These results demonstrate that PS activates the
nitric oxide (NO) synthesis in lymphatic endothelium iso-
lated cells and the LVs contractility might be the possible
mechanisms responsible for PS of lymphatic clearance of
macromolecules from the brain. The PS-mediated dilation
of LV can be due to an increase in the activity of endothelial
NO synthase [39]. NO is a vasodilator that acts via stimu-
lation of soluble guanylate cyclase to form cyclic-guano-
sine monophosphate, which activates protein kinase G
causing the opening of calcium-activated potassium
channels and reuptake of Ca2+ from the cytosol. The
decrease in the concentration of Ca2+ prevents myosin
light-chain kinase from phosphorylating the myosin
molecule, leading to the relaxation of LVs [40]. The
PS-mediated relaxation of LV is closely associated with an
increase in the permeability of the lymphatic endothelium
via a decrease in the expression of tight junction proteins
[9, 10]. The increased lymphatic permeability is a driving
force for drainage and clearing functions of LVs. These
facts explain our data, which demonstrate that PS activates
the clearance of liposomes from the subarachnoid space by
modulating the tone of the cervical LVs. This also partly
explains why the PS-treated group showed lower levels of
Evans Blue in the brain comparing with the untreated
group.
In summary, our results demonstrate the unique
properties of the lymphatic system to delivery of tracers
and liposomes to the brain meninges, brain tissues, and
glioma tissues in rats. Using a quantum-dot-based 1267 nm
laser (photosensitizer-free generation of singlet oxygen),
we clearly show the PS of lymphatic delivery of liposomes
to glioma as well as lymphatic clearance of liposomes from
the brain. These pilotfindings open promising perspectives
for photomodulation of a lymphatic delivery of drugs and
nanocarriers to the brain with pathologies bypassing the




Pathogen-freemaleWistar rats (200–250 g, twomonths old)were used
in all experiments and were obtained from the National Laboratory
Animal Resource Center (Pushchino, Moscow, Russia). The animals
were housed under standard laboratory conditions, with access to
food and water, ad libitum. All procedures were performed in accor-
dance with the “Guide for the Care and Use of Laboratory Animals”.
The experimental protocols were approved by the Bioethics Commis-
sion of the Saratov State University (Protocol No. 7). The experiments
were performed in the following groups: (1) and (2) – The Evans Blue
(1) and liposomes (2) injection in dcLN for ex vivo confocal analysis of
tracers presence in themeninges, in the PVS ofMLVs, and in the brain,
respectively; (3) and (4)– The liposomes injection in dcLN and ligation
of the cervical LVs above (3) and below (4) dcLN for in vivo confocal
images of liposomes in the meninges, respectively; (5) and (6) – The
liposomes injection in dcLN for ex vivo confocal analysis of the brain in
rats with fluorescent glioma without PS (5) and after PS (6), respec-
tively; (7) The liposomes injection in the cisternamagna for in vivo and
ex vivo confocal imaging of the cervical LVs in the same rats; n = 7 in
each group.
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4.2 Synthesis of GM1-liposomes
Fluorescently-labeled GM1-liposomes were prepared as described
earlier [22]. Briefly, a lipid film obtained from egg yolk phosphatidyl-
choline (Lipoid GmbH, Germany)– ganglioside GM1 frombovine brain
(Sigma Chemical Co., St. Louis, MO, USA), 9:1 (by mol), and 1 mol% of
BODIPY-phosphatidylcholine (λex = 497 nm, λem = 505 nm [41, 42]) was
hydrated in physiological saline (phosphate buffer with 1 mM EDTA,
pH 7.3; total lipid concentration 25 mM) (Figure 5). The resulting
suspension was subjected to seven cycles of freezing/thawing (liquid
nitrogen/+40 °C) and extruded 10 times through polycarbonate
membrane filters (Nucleopore, USA) with a 100 nm pore diameter
using Avanti Mini-extruder (Northern Lipids, Canada). Particle size
was measured by dynamic light scattering with the Brookhaven
equipment (Brookhaven Instruments Corp. 90Plus Particle Sizing
Software ver. 4.02, NY, USA) in at least three runs per sample: effective
diameter and polydispersity indexes were 90.2 ± 1.8 nm and 0.071,
respectively. The Zeta potential of liposomes of this composition
measured using ZetaPALS analyzer (Brookhaven Instruments Corp.,
Holtsville, NY) [22], was – 48.3 ± 0.9 mV (according to calculations
using Smoluchowski approximation).
4.3 Implantation of C6-TagRFP glioma [43]
The rats were pre-treated by premedication with Seduxen (Gedeon
Richter, Hungary) in a dose of 50 μg/mL. Afterward, rats were deeply
anesthetized with intraperitoneal Zoletil (Virbac, France) in a dose of
100 μg/kg and moved into a stereotaxic head holder and immobilized
on the stereotactic system (Narishige, Japan) by fixation of the head.
The scalp of the anesthetized rat was shaved and scrubbed with
betadine three times followedby an alcohol rinse.Hairwas removedat
the site of the planned operation and the scalp was cut in this area. An
incision was made over the sagittal crest from the bregma to the
lambdoidal suture and the periostealmembranewas removed.A small
dental drill was used to create a burr hole through the bone without
tearing the dura matter in the exposed cranium 0.5 mm anterior and
3 mm lateral to the bregma.
The cell line C6 of rat glioma was obtained from the Russian Cell
Culture Collection of Vertebrates, Institute of Cytology, Russian Acad-
emy of Sciences (St. Petersburg, Russia). A transfected C6-TagRFP cell
line was used for the study of the growth of fluorescent glioblastoma
[43]. C6 cells were cultured in Dulbecco’s modified eagle medium
(DMEM, PanEco, Russia) containing 2.5% fetal calf serum (Biosera),
4 mM glutamine (PanEco, Russia), penicillin (50 IU/mL) and strepto-
mycin (50mg/mL) (PanEco,Russia). Versen’s solution (PanEco, Russia)
with theadditionof0.25% trypsin (Gibco)wasused to removecells from
the surface of the culture plastic. Cells were cultured in a humid envi-
ronment in a CO2 incubator at a temperature of 37 °C, with a content of
5% CO2. The number of cells was counted on the TC20 Bio-Rad auto-
mated cell counter, and the viability analysis was determined using a
trypan blue dye. Rat C6 glioma cells were transfected with pTagRFP-C
DNA plasmid using the method of liposomal transfection followed by
selection using geneticin (G418 antibiotic, neomycin analog) on the
base research center “Symbiosis” Institute of Bioorganic Chemistry,
Russian Academy of Sciences (Saratov, Russia). The resulting cell line
C6-TagRFP has stable cultural and morphological characteristics.
The glioma cells (5 × 105 cells per rat) were injected at a depth of
4.5 mm from the brain surface into the caudate-putamen area with a
Hamilton microsyringe in a volume of 15 μL at a rate of 3 μL/min. The
duration of implantation did not exceed 10–15 min. The physiological
saline (15 µL, Sigma-Aldrich, US) was injected into the same region of
Figure 5: Molecular structures of lipid bilayer components of fluorescently labeled GM1-liposomes based on egg phosphatidylcholine:
A – BODIPY-phosphatidylcholine {1-palmitoyl-2-[15-(4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-yl)pentadecanoyl]-sn-
glycero-3-phosphocholine}; B – shown is a representative structure of ganglioside GM1 from bovine brain.
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the brain in the shamgroups. Thereafter, the burr holewas sealedwith
sterile bone wax and tissue glue and the wound sutured closed with
3–0 absorbable suturematerial. After the implantation of glioma cells,
the wound was closed and treated with a 2%-brilliant green solution.
The rats were removed from the stereotaxic head holder, given
0.01 mg/kg buprenorphine, s.c., and 50K bicillin, i.m. and returned to
their cages after recovery in the temperature-controlled recovery cage
and moved back to the animal facility after recovery. The animal
was placed in a clean cage. The growth of fluorescent glioblastoma
C6-TurboFP635 in rats was assessed by confocal microscopy using the
Leica SP5 confocal laser scanning microscope (Leica, Germany) via
optical window using adapted protocol for two-photon imaging of
neural activity in awake behavior rodents [44].
4.4 Immunohistochemistry (IHC) and confocal imaging
For confocal imaging of MLVs, we used the protocol for the IHC
analysiswith themarkers for lymphatic vessel endothelial hyaluronan
receptor 1 (LYVE1), for the pericytes in the blood vessels, such as the
neuron-glial antigen 2 (NG2), and for astrocytes by glial fibrillary
acidic protein (GFAP). For the IHC analysis, brain and dcLN tissue
were collected and free-floating sections were prepared. The tissue of
the brain and dcLNwere fixed for 48 h in a 4% saline solution-buffered
formalin, then sections of the brain and dcLN with a thickness of
40–50 μm were cut on a vibratome (Leica, Germany). The tissues
of dcLN were previously poured into 2% agarose on the saline solu-
tion. Sections were processed according to the standard immunohis-
tochemical protocol with the corresponding primary and secondary
antibodies. The sections of themouse brain,meninges, and dcLNwere
imaged using a Leica SP8 confocal laser scanning microscope (Leica,
Germany). The antigen expression was evaluated on free-floating
sections according to the standard method of simultaneously com-
bined staining of the drug (Abcamprotocols for free-floating sections).
The nonspecific activity was blocked by a 2-h incubation at room
temperature with 10% BSA in a solution of 0.2% Triton X-100 in
phosphate-buffered saline (PBS). Solubilization of cell membranes
was carried out during 1-h incubation at room temperature in a
solution of 1% Triton X-100 in PBS. Incubation with primary
antibodies in a 1:500 dilution took place overnight at 4 °C: with rat
antibodies to Lyve-1 (1:500; NBP1-43411AF488; Novus Biologicals,
Centennial, Colorado, USA); mouse antibodies to NG2 (1:500;
ab50009; Abcam, Biomedical Campus Cambridge, Cambridge, UK)
and rabbit antibodies to GFAP (1:500; ab207165; Abcam, Biomedical
Campus Cambridge, Cambridge, UK). At all stages, the samples were
washed 3–4 times with 5-min incubation in a washing solution. After
that, the corresponding secondary antibodies were applied (goat
anti-rat IgG (H + L) Alexa Four 405; goat anti-mouse IgG (H + L) Alexa
Four 555, and goat anti-rabbit IgG (H + L) Alexa Four 647; Invitrogen,
Molecular Samples, Eugene, Oregon, USA). At the final stage, the
sections were transferred to the glass and 15 µL of mounting liquid
(50% glycerin in PBS with the diamidino-2-phenylindole (DAPI) at a
concentration of 2 μg/mL) was applied to the section, then the prep-
aration was covered with a cover glass and confocal microscopy was
performed.
For IHC with BODIPY-liposomes, the brains were fixed with 4%
neutral buffered formalin. After fixation, the brains were cry-
oprotected using 20% sucrose in PBS (10 mL/brain mouse) for 48 h at
4 °C. The brains were frozen in hexane cooled to −32 to −36 °C. Cry-
section (14 µm) of parietal cortex were collected on poly-L-Lys,
Polysine Slides (Menzel-Glaser, Germany) using cryotome (Thermo
Scientific Microm HM 525, Germany) and a liquid for fixing a Tissue-
Tek sample (Sakura Finetek, USA). Cryosections were blocked in
150 µL 10% BSA/PBS for 1 h, then incubated overnight at 4 °C with
130 µL anti-rat antibodies to Lyve-1 (1:500; NBP1-43411AF488; Novus
Biologicals, Centennial, Colorado, USA); mouse antibodies to NG2
(1:500; ab50009; Abcam, Biomedical Campus Cambridge, Cambridge,
UK) and rabbit antibodies to GFAP (1:500; ab207165; Abcam,
Biomedical Campus Cambridge, Cambridge, UK). After several rinses
in PBS, slides were incubated for 1 h with 130 µL fluorescent-labeled
secondary antibodies on 1% BSA/PBS goat anti-rat IgG (H + L) Alexa
Four 405; goat anti-mouse IgG (H + L) Alexa Four 555, and goat anti-
rabbit IgG (H + L) Alexa Four 647; Invitrogen, Molecular Samples,
Eugene, Oregon, USA). At the final stage, the sectionswere transferred
to the glass and 15 µL of mounting liquid (50% glycerin in PBS with
DAPI at a concentration of 2 μg/mL) was applied to the section, then
the preparation was covered with a cover glass and confocal micro-
scopy was performed.
4.5 Quantitative analysis of confocal images
The analysis of fluorescence of BODIPY-liposomes in the testes tissues
was carried out on amicroscopic systemwith automatic analysis of the
obtained photos of Ariol SL50 (Genetix, UK). The software module
PathVysion (Music, Inc. Applied Imaging) determined the total area of
the histological preparation and calculation the fluorescence intensity
in the whole brain or dcLN slices. In all cases, 10 ROIs were analyzed.
For the quantitative analysis of intensity signal from Evans Blue
in the meninges, ImageJ was used for image data processing and
analysis. The areas of specific signals from dye were calculated using
the plugin “Analyze Particles” in the “Analyze” tab, which calculates
the total area of Evans Blue fluorescence intensity tissue elements –
the indicator “Total Area”. In all cases, 10 ROIs were analyzed.
The diameters of the cervical LVs were measured by tracing the
width of vessels along the direction of the vessel running from the
cortical to medulla sinuses every 20-µm interval in the entire
lymphatic network ofwhole-mount dcLN samples as ROI using ImageJ
software (NIH).
4.6 Real-time images of the cervical lymphatic vessels
and the meninges
Images of the cervical LVs and Evans Blue in the meninges were
acquired in vivo using Nikon A1R confocal microscope with a 10 × 0.45
dry lens (Nikon Corp., Japan). Images were acquired continuously
with 3 s intervals since the fluorescent liposomes or Evans Blue was
administered in dcLN. The intensity of fluorescence was measured in
arbitrary units with homemade software developed using LabVIEW
and NI Vision toolkit (National Instruments Corp., USA). The intensity
of fluorescence was measured with software developed using Lab-
VIEW and NI Vision (National instruments Corp., USA). Series of two-
channel images captured with a confocal microscope was converted
into tiff format with Fiji [45]. To minimize the effect of animal move-
ment pattern recognition-based coordinate system correction was
performed. It allows to link rectangular ROI to the vessels pattern and
to ensure correct intensity measurements. The intensity of fluores-
cence was measured in both channels (BODIPY and Evans Blue) over
rectangular ROI of 20–40 μm in size rotated to fit the vessel as it is
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shown in Figure 4c. The resulting intensity was then calculated as an
averaged value over approximately 1500 pixels constituting ROI. To
correct some minor intensity fluctuations caused by vessel displace-
ment in the axial direction the ratio of BODIPY to Evans Blue intensity
was calculated. The ratio represents variations of liposome intensity
fluctuations induced with both liposome movement and bleaching
with respect to the fluorescence of Evans Blue that is not subjected to
photobleaching and that was administered beforehand to ensure
stable staining of LVs.
4.7 Spectrofluorometric assay of Evans Blue
extravasation
Evans Blue dye (Sigma Chemical Co., St. Louis, Missouri, 2 mg/25 g
mouse, 1% solution in physiological 0.9% saline) was injected into the
femoral vein and circulated in the blood for 30min. Then, the ratswere
decapitated, and their brains were quickly collected. At the end of the
circulation time, mice were decapitated, their brains and blood were
quickly collected and placed on ice (no anticoagulation was used
during blood collection). Prior to brain removal, the brain was
perfused with saline to wash out the remaining dye in the cerebral
vessels. The level of Evans Blue in the brain was evaluated in accor-
dance with the recommended protocol [46].
4.8 Laser radiation scheme and dose calculation
A fiber Bragg grating wavelength locked high-power laser diode
(LD-1267-FBG-350, Innolume,Dortmund, Germany) emitting at 1267 nm
was used as a source of irradiation. The laser diodewas pigtailedwith a
single-mode distal fiber ended by the collimation optics to provide a
5 mmbeam diameter at the specimen. The rats were recovered after the
glioma cells transplantation for seven days. Thereafter, the head of rats
was shaved and the scalp was removed, then they were fixed in a
stereotaxic frame and irradiated in the area of the glioma cells injection
with a near-infrared laser using the algorithm: 17 min PS + 5 min
pause + 17 min PS + 5 min pause + 17 min PS of 100 mW laser power
intensity with the total dose applied of 1611 J/cm2 (on the surface of
skull) and 470 J/cm2 (on the surface of the brain, taking in account skull
absorption of 65% and scattering initial laser irradiation from 5 to 6mm
[11]) under inhalation anesthesia (1% isoflurane at 1 L/minN2O/O2 – 70/
30 ratio) [11]. The laser doses were calculated as follows:
D = 0.35∗ P∗T
1.2∗S
(1)
where D is irradiation dose; 0.35 and 1.2 are scull absorbance and
scattering coefficients, correspondently; S is square of the laser beam
on the brain cortex (cm2); P is a laser irradiation power on the scull
surface (W); and T is the full laser irradiation time (s).
4.9 Statistical analysis
The results are presented as mean ± standard error of the mean. Dif-
ferences from the initial level in the same groupwere evaluated by the
Wilcoxon test. Intergroup differenceswere evaluated using theMann–
Whitney test and the two-way analysis of variance (ANOVA-2) and
post hoc analysiswithDuncan’s rank test. The significance levelswere
set at p < 0.05–0.001 for all analyses.
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